je.st
news
Achillion Pharma Takeout Less Likely After Subpar Hep C Drug Results
2014-12-23 14:33:46| Biotech - Topix.net
Tamp down your hopes and dreams if you were expecting Achillion to be the next hepatitis C buyout candidate. Achillion shares are up 18% to $16.84.
Tags: results
drug
pharma
hep
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||